The 4-day Medlab Middle East exhibition came to a successful conclusion.
HymonBio’s star product, Pan-Cancer Screening Test, performed brilliantly at the exhibition.
With its amazing cutting-edge technology, the Pan-Cancer Screening Test can detect 28 common and highly prevalent cancers with just one tube of blood. On the Q-PCR platform, through in-depth analysis of methylation-cancer mutations of more than 400 tumor genes, relying on the company’s original BIO-AI algorithm, accurate and automatic interpretation was achieved.
This breakthrough technological achievement has won high recognition and sincere praise from medical experts around the world. The company took this opportunity to reach cooperation intentions with several international companies.
Medlab Middle East may have ended, but HymonBio never stops.
Hangzhou CACLP will open on March 22.
We will wait for you at 2-F0503 and look forward to talking with you about new industrial developments.
Post time: Feb-07-2025